Abstract 176P
Background
In China, surgical resection and ablation are widely used to treat HCC; however, relapse rates are high for patients with residual elevated AFP 2 months post-treament. LEN has been shown to reduce AFP levels in patients with advanced HCC. We therefore investigated the efficacy of LEN for preventing recurrence in patients with HCC and elevated AFP after surgery or ablation.
Methods
This single-center, retrospective study, conducted between Nov 2018 and Jan 2020, included medical records from 84 patients with HCC who achieved complete radiologic response following resection or radiofrequency ablation, had high residual AFP (>20 ng/mL) 8 weeks post-surgery and received LEN according to local labelling (n=23), adjuvant transarterial chemoembolization (TACE; n=25) or no treatment (Control group, n=36). A further group of patients with HCC R0 resection (AFP negative post-surgery) was also included (n=22). AFP response was defined as >20% reduction in AFP ≤8 weeks from initiation of LEN. Recurrence free survival (RFS) was calculated from initiation of treatment (LEN and TACE groups) or the date of surgery (Control and R0 groups) until first confirmed local, regional or distant tumor recurrence.
Results
Median follow-up in all patients was 11.2 months. Patient baseline characteristics were similar between groups, except for baseline BCLC stage. Among patients receiving LEN, 61% (14/23) achieved an AFP response. The rate of 1-year RFS was higher for patients in the LEN group who achieved an AFP response (71.4% [10/14]) compared with the TACE (36.0% [9/25]) and Control (50.0% [18/36]) groups. Median RFS had not been reached in the LEN, TACE, and R0 groups. At data cutoff, 9 (64.3%) patients receiving LEN who achieved an AFP response were recurrence free, and follow-up is on-going.
Conclusions
LEN led to an AFP response in 61% of patients with HCC and residual elevated AFP post surgery/ablation, and this was associated with a high 1-year RFS. Therefore, AFP response may provide a biomarker to predict response to LEN in this setting and further investigation in prospective trials is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session